FDA approves Auvelity for Alzheimer's disease-related agitation

MedicalXpress | 五月 07, 2026

The U.S. Food and Drug Administration has approved the expanded use of Axsome Therapeutics' Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride) extended-release tablets to treat adults with agitation associated with dementia due to Alzheimer's disease.